Sign up Australia
Proactive Investors - Run By Investors For Investors

Pharmaxis seeing a great deal of interest from potential LOXL2 program partners

Gary Phillips, chief executive of Pharmaxis Ltd (ASX:PXS) tells Proactive one of the key events for the company this year will be the mid‐year read out from the phase 1 studies that are underway on the two lead candidates from their anti fibrotic LOXL2 program.

''I've spent the last 12-18 months talking to potential partners'', Phillips says.

''We're looking for a company active in either NASH or IPF which is looking for an anti-fibrotic to add to their pipeline''.

''We've got about 10 companies which are seriously interested in the program we've been running … many of them are already under confidentiality agreements and some of them testing our compound in their laboratories so I can see a great deal of interest in this particular program''.

Meet Great Boulder Resources Ltd, Mainstream Group Holdings Ltd, Blackstone Minerals Ltd, Pacific American Coal Ltd and Reward Minerals Ltd at our event, Sydney , 19 November 2018. Register here »
View full PXS profile View Profile

Pharmaxis Ltd Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use